- Evaxion Biotech A/S (NASDAQ:EVAX) has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022.
- We currently have two product candidates in the DNA technology platform, EVX-02, and EVX-03. Based on preclinical results, the company has decided to move EVX-03 in an upcoming clinical trial in a new indication.
- EVX-03 is optimized with an APC-targeting unit (Antigen-Presenting Cell), which has shown promising preclinical data, significant tumor reduction at very low doses, and a clear dose-response relationship in all preclinical models.
- Evaxion has decided to continue the development of EVX-03 in patients with advanced disease and plans to target non-small cell lung cancer (NSCLC) with EVX-03.
- EVX-02 is currently being tested in a phase 1/2a trial in patients with resectable melanoma. A full clinical readout is expected in Q2 2023.
- Earlier this month, Evaxion announced an equity purchase agreement with Lincoln Park Capital Fund for up to $40 million of its American Depositary Shares.
- Price Action: EVAX shares are up 4.55% at $1.84 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Evaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung Cancer
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks